Ganferobole is a Leucyl-tRNA synthetase inhibitor and it is not approved yet. Safety and efficacy data are still not mature.

**DISEASE BURDEN**

In 2021, an estimated 10.6 million people fell ill with TB worldwide, of which 450,000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.

**SERVICE DELIVERY ENABLERS**

Ganfeborole is being investigated for use as part of an oral TB treatment. Companion drugs may include bedaquiline and delamanid, which are available as generics, although still not widely accessible.

**INTELLECTUAL PROPERTY LANDSCAPE**

Ganfeborole primary patents have been filed or granted in several LMICs and are expected to expire between 2031-2036. Secondary patents may be filed.

**REGULATORY**

The product does not have regulatory approval yet and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

**MANUFACTURING**

There is currently no adequate data to assess manufacturing complexity.

**MARKET**

This medicine is still in the R&D pipeline and therefore little is known about its potential positioning in treatment protocols, pricing, and overall access plans.

**31 October 2023**

**Other MPP prioritised candidates**

**Abbreviations list**